Literature DB >> 32939939

VI-RADS for Bladder Cancer: Current Applications and Future Developments.

Valeria Panebianco1, Martina Pecoraro1, Francesco Del Giudice2, Mitsuru Takeuchi3, Valdair F Muglia4, Emanuele Messina1, Stefano Cipollari1, Gianluca Giannarini5, Carlo Catalano1, Yoshifumi Narumi6.   

Abstract

Bladder cancer (BCa) is among the ten most frequent cancers globally. It is the tumor with the highest lifetime treatment-associated costs, and among the tumors with the heaviest impacts on postoperative quality of life. The purpose of this article is to review the current applications and future perspectives of the Vesical Imaging Reporting and Data System (VI-RADS). VI-RADS is a newly developed scoring system aimed at standardization of MRI acquisition, interpretation, and reporting for BCa. An insight will be given on the BCa natural history, current MRI applications for local BCa staging with assessment of muscle invasiveness, and clinical implications of the score for disease management. Future applications include risk stratification of nonmuscle invasive BCa, surveillance, and prediction and monitoring of therapy response. LEVEL OF EVIDENCE: 3 TECHNICAL EFFICACY STAGE: 2.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  VI-RADS score; bladder neoplasms; magnetic resonance imaging; staging

Mesh:

Year:  2020        PMID: 32939939     DOI: 10.1002/jmri.27361

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival.

Authors:  Sungmin Woo; Soleen Ghafoor; Jeeban P Das; Natalie Gangai; Alvin C Goh; Herbert Alberto Vargas
Journal:  Urol Oncol       Date:  2021-11-05       Impact factor: 3.498

Review 2.  The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations.

Authors:  Francesco Del Giudice; Rocco Simone Flammia; Martina Pecoraro; Marco Moschini; David D'Andrea; Emanuele Messina; Lucia Martina Pisciotti; Ettore De Berardinis; Alessandro Sciarra; Valeria Panebianco
Journal:  World J Urol       Date:  2022-03-16       Impact factor: 3.661

3.  Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in "High-Risk" Patients Following Radical Cystectomy: A Retrospective Cohort Study.

Authors:  Chung Un Lee; Dong Hyeon Lee; Wan Song
Journal:  Front Oncol       Date:  2021-08-20       Impact factor: 6.244

4.  Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer.

Authors:  Yang Zhao; Bin Zhao; Wei-Hua Yan; Yan Xia; Zhi-Hui Wang; Guo-Yang Zheng; Wen-Da Wang; Yu-Shi Zhang
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

5.  Multiparametric magnetic resonance imaging of plasmacytoid urothelial carcinoma with histopathological correlation: A case report.

Authors:  Koichi Ito; Kazuyuki Ohgi; Yuan Bae; Akira Ishikawa; Koichiro Kimura; Akiyoshi Yamashita; Hiroyuki Yokote; Shunji Tsukuda; Tomohiro Higuchi; Yoshiro Kikuoka; Naoki Kawakami; Masahiko Harada
Journal:  Radiol Case Rep       Date:  2022-04-13

Review 6.  VI-RADS score system - A primer for urologists.

Authors:  Refky Nicola; Martina Pecoraro; Sara Lucciola; Rodolfo Borges Dos Reis; Yoshifumi Narumi; Valeria Panebianco; Valdair Francisco Muglia
Journal:  Int Braz J Urol       Date:  2022 Jul-Aug       Impact factor: 3.050

Review 7.  Study Progress of Noninvasive Imaging and Radiomics for Decoding the Phenotypes and Recurrence Risk of Bladder Cancer.

Authors:  Xiaopan Xu; Huanjun Wang; Yan Guo; Xi Zhang; Baojuan Li; Peng Du; Yang Liu; Hongbing Lu
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.